NCT05447520View on ClinicalTrials.gov

Montelukast Use in Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Montelukast

Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2

DRUG

Placebo

Oral tablet once daily

DRUG

Conventional DMARDs

methotrexate, leflunomide, hydroxychloroquine or sulfasalazine

Trial Locations (1)

35516

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Noha Mansour

OTHER

NCT05447520 - Montelukast Use in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter